Delivery Order SPE2DB22D2211-SPE2DB24FNYD8

Award Date 7/16/24
Potential Completion Date 8/6/24
Potential Value $3.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $2,026.85, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ENVARSUS XR 1 MG TABLET 100S, a pharmaceutical product, with a completion date of December 4, 2024. The contract is a delivery order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ENVARSUS XR 4 MG TABLET 100S, a prescription medication, with a ceiling value of $3,423.90 and a period of performance through March 7, 2025. The contract is a Delivery Order issued under an existing Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support...
This federal contract award, valued at $3,230.68, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award is for the delivery of ENVARSUS XR 4 MG TABLET 100S, a medication, with a completion date of August 19, 2024. The contract is a Delivery Order placed under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which has a total ceiling value of $999,999,999 and runs through...
This federal contract award, valued at $1,553.40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order contract for the supply of ENVARSUS XR 1 MG TABLET 30S, a pharmaceutical product. This contract is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of ENVARSUS XR 0.75 MG tablets. The contract, valued at $1,103.64, is a Firm Fixed Price Delivery Order without any set-aside requirements. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999, which serves as a primary vehicle for providing a comprehensive...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ENVARSUS XR 1 MG TABLET 30S, a prescription medication. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $1,035.60 and a period of performance through July 10, 2025. This contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,288.86 firm-fixed-price delivery order is for the supply of ENVARSUS XR 1 MG TABLET 100S, a pharmaceutical product. The award has an ultimate completion date of February 27, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, worth $3,000.81, is for the delivery of ENVARSUS XR 4 MG TABLET 100S, a prescription medication. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of April 18, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,933.80, is for the delivery of ENVARSUS XR 0.75 MG TABLET 100S, a pharmaceutical product. The contract type is a Delivery Order with a Firm Fixed Price pricing type. The ultimate completion date is January 30, 2025. This award is associated with a larger Indefinite Delivery...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,288.86 firm fixed-price delivery order is for the supply of ENVARSUS XR 1 MG TABLET 100S, a prescription medication. The contract is non-set-aside, indicating open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
  • SPE2DB22D2211
    Indefinite Delivery Contract
  • SPE2DB22D2211-SPE2DB24FNYD8
    Delivery Order

This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the delivery of ENVARSUS XR 4 MG TABLET 100S. The contract has a ceiling value of $3,636.05 and is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical valued at up to $999,999,999 through December 2025. This IDC enables the DLA to efficiently procure a comprehensive range of medical commodities, including prescription drugs and pharmaceutical products, to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation and is scheduled for completion on August 6, 2024.

Generated 10/15/24, 9:45 PM